Brady L. Stein, MD, MHS, received Internal Medicine training and fellowship training in hematology from the Johns Hopkins University School of Medicine. During fellowship, he was an awardee of the K12 Blood Scholars Program, focusing on clinical research in hematology. During that program, he received an MHS in Clinical Investigwation at the Johns Hopkins Bloomberg School of Public Health. He moved to Northwestern University Feinberg School of Medicine in the summer of 2010 as an Attending Physician in Hematology/Oncology.Susan O’Brien, MD, is Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research at UC Irvine Health, Irvine, California and former Chair of the NCCN Guidelines for chronic myelogenous leukemia.The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.Peter Greenberg, MD, is Professor of Medicine, Hematology Division, at Stanford Cancer Institute, and Chair of the NCCN Guidelines Panel for Myelodysplastic Syndromes.Ruben A. Mesa, MD, is Professor of Medicine of Mayo Medical School and chair of the Division of Hematology/Oncology in the Department of Internal Medicine at Mayo Clinic and deputy director at Mayo Clinic Cancer Center in Arizona. Dr. Mesa is active in the Arizona Cancer Coalition. Dr. Mesa attended University of Illinois at Urbana-Champaign for his undergraduate degree and earned his medical degree at Mayo Medical School. He completed both a residency in internal medicine and a fellowship in hematology/medical oncology at Mayo Graduate School of Medicine.
TefferiACervantesFMesaR. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood2013;122:1395–1398.
TefferiACervantesFMesaR. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. 2013;122:1395–1398.